Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59
The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Abstract
Human influenza subunit vaccines are not fully protective in either the very young or elderly populations where risk is greatest. The use of an adjuvant to enhance antibody titer is an attractive option to increase vaccine efficacy. A series of squalene/H2O emulsions stabilized either by the amphipathic muramyl peptide MTP-PE (sodium N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanyl-2-(1',2'-dipalmitoyl- sn- glycero-3'phospho) ethylamide) or by mixtures of the sorbitan oleate surfactants Tween 80 and Span 85 have been tested as adjuvants with influenza vaccine. Combination of influenza vaccine with the Tween/Span stabilized emulsions has resulted in significantly higher antibody titers to vaccine in an extensive series of naive animal models. The use of submicron emulsion droplets is significant in determination of adjuvant activity while the presence of the muramyl peptide is not required for adjuvant activity. The 200-300 nm diameter emulsion formulation MF59 containing only the low toxicity components squalene, Tween 80 and Span 85 has been shown to enhance titers from 5 to 250 times that achievable with vaccine alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [162]
Citations
Cites
Adjuvants — a balance between toxicity and adjuvanticity
Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., & Gupta, C. K. (1993) · Vaccine · doi:10.1016/0264-410x(93)90190-9 · Cited by 545
Factors affecting emulsion stability, and the HLB concept
Boyd, J., Parkinson, C., & Sherman, P. (1972) · Journal of Colloid and Interface Science · doi:10.1016/0021-9797(72)90122-1 · Cited by 360
Fidler, I. J., Sone, S., Fogler, W. E., & Barnes, Z. L. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1680 · Cited by 324
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Self-citationInfluenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports
Strassburg, M. A., Greenland, S., Sorvillo, F. J., Lieb, L. E., & Habel, L. A. (1986) · Vaccine · doi:10.1016/s0264-410x(86)80002-0 · Cited by 154
Valensi, J. P., Carlson, J. R., & Nest, G. A. V. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.9.4029 · Cited by 143
Self-citationHunter, R. L., & Bennett, B. T. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.6.3167 · Cited by 122
Cate, T. R., Couch, R. B., Parker, D., & Baxter, B. D. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.4.737 · Cited by 107
The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador, L., Burke, R. L., Ott, G. S., & Nest, G. V. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.5.1720 · Cited by 93
Self-citationDavenport, F. M., Hennessy, A. V., & Askin, F. B. (1968) · The Journal of Immunology · doi:10.4049/jimmunol.100.5.1139 · Cited by 81
Research works printed but not linked: 1
- Beckendorf, 1995, Toxicology findings in the use of an oil in water adjuvant, MF59, The Toxicologist, 15, 69
Cited by
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Cox, R. J., Brokstad, K. A., & Ogra, P. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01382.x · Cited by 553
Singh, M., & O'Hagan, D. (1999) · Nature Biotechnology · doi:10.1038/15058 · Cited by 506
“Subsequently, a squalane o/w emulsion has been developed (MF59) without the presence of additional immunostimulators, and this formulation has proved to be a potent adjuvant with an acceptable safety profil”
MethodThe mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Self-citation
Metadata
- Authors
- Ott, G., Barchfeld, G. L., & Nest, G. V.
- Corresponding author
- Ott, Gary
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 1995-01
- Volume
- 13
- Issue
- 16
- Pages
- 1557-1562
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2013872507
- Cited by
- 147
- References
- 32
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 10
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Keywords
- influenza vaccination, MF59, adjuvants, humoral immune response, antibody titers, squalene, Tween 80, Span 85, muramyl peptides, subunit vaccine, vaccine efficacy
- MeSH terms
- Acetylmuramyl-Alanyl-Isoglutamine, Adjuvants, Immunologic, Amino Acid Sequence, Animals, Antibodies, Viral, Antibody Formation, Chemistry, Pharmaceutical, Emulsions, Enzyme-Linked Immunosorbent Assay, Female, Guinea Pigs, Cricetinae, Influenza Vaccines, Male, Mesocricetus, Mice, Inbred BALB C, Molecular Sequence Data, Influenza A virus, Influenza B virus, Phosphatidylethanolamines, Rabbits, Squalene, Water, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. https://app.cochat.ai/papers/10.1016/0264-410x(95)00089-j
- The paper
- Ott, G., Barchfeld, G. L., & Nest, G. V. (1995). Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine. https://doi.org/10.1016/0264-410x(95)00089-j
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.